TMPRSS2 and prostate carcinoma: Studies have found that in about 50% of prostate cancer cases, intronic deletions between the TMPRSS2 and ERG genes lead to the fusion of the TMPRSS2 promoter with ERG, a fusion that exists in over 90% of ERG-overexpressing prostate cancers (46).